Brief Report: Real-World Treatment Patterns and Clinical Outcomes for Patients With Advanced ALK-Rearranged NSCLC in British Columbia
Introduction: EML4-ALK rearrangements represent an oncogenic driver alteration in 5% of NSCLC cases. We aim to better understand real-world treatment patterns and outcomes of ALK fusion-positive (ALK+) patients with advanced-stage NSCLC. Methods: We performed a retrospective population-based chart r...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-04-01
|
| Series: | JTO Clinical and Research Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666364324000675 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850268910636498944 |
|---|---|
| author | Peiyao Wang, BSc Curtis Hughesman, PhD Stephen Yip, MD, PhD, FRCPC William W. Lockwood, PhD Sophie Sun, MD, MSc, FRCPC |
| author_facet | Peiyao Wang, BSc Curtis Hughesman, PhD Stephen Yip, MD, PhD, FRCPC William W. Lockwood, PhD Sophie Sun, MD, MSc, FRCPC |
| author_sort | Peiyao Wang, BSc |
| collection | DOAJ |
| description | Introduction: EML4-ALK rearrangements represent an oncogenic driver alteration in 5% of NSCLC cases. We aim to better understand real-world treatment patterns and outcomes of ALK fusion-positive (ALK+) patients with advanced-stage NSCLC. Methods: We performed a retrospective population-based chart review of ALK+ patients with locally advanced or metastatic NSCLC in British Columbia (BC), Canada. Patients diagnosed from January 2014 to May 2023 were identified through the BC Cancer Genetics Laboratory database, and data were collected up to December 2023. Results: A total of 216 patients with stage IIIB, IIIC, or IV ALK+ lung NSCLC were identified. Median age was 60 (range: 24–91) years, 151 (68.9%) had never smoked, and 95 (43.9%) were Asian. The median overall survival was 49.4 months with median follow-up time of 55.4 months. Majority of the cohort (n = 198, 91.7%) received palliative systemic therapy, all of which included at least one ALK tyrosine kinase inhibitor (TKI). The most common first-line regimen was alectinib (n = 97, 49.0%) followed by crizotinib (n = 84, 42.4%); only four and one patient received lorlatinib and brigatinib first line, respectively. Alectinib was frequently prescribed overall, with 80.3% of patients receiving it in any treatment line. Time to treatment discontinuation was significantly longer (p < 0.0001) on first-line alectinib at 22.9 months as compared with 10.9 months for crizotinib. Conclusions: Patients with ALK+ advanced NSCLC in BC have durable responses to ALK TKIs. Despite approval of all ALK TKIs for first-line use since 2021, alectinib is largely the favored agent in BC. Further real-world investigations can refine treatment strategies and shape policies around ALK TKIs for patients with ALK+ NSCLC. |
| format | Article |
| id | doaj-art-e5e6813933ff41e79d40c53b065cd30c |
| institution | OA Journals |
| issn | 2666-3643 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Elsevier |
| record_format | Article |
| series | JTO Clinical and Research Reports |
| spelling | doaj-art-e5e6813933ff41e79d40c53b065cd30c2025-08-20T01:53:19ZengElsevierJTO Clinical and Research Reports2666-36432025-04-016410069710.1016/j.jtocrr.2024.100697Brief Report: Real-World Treatment Patterns and Clinical Outcomes for Patients With Advanced ALK-Rearranged NSCLC in British ColumbiaPeiyao Wang, BSc0Curtis Hughesman, PhD1Stephen Yip, MD, PhD, FRCPC2William W. Lockwood, PhD3Sophie Sun, MD, MSc, FRCPC4Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, British Columbia, CanadaCancer Genetics and Genomics Laboratory, BC Cancer, Vancouver, British Columbia, CanadaDepartment of Pathology & Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, CanadaDepartment of Integrative Oncology, BC Cancer Research Institute, Vancouver, British Columbia, Canada; Department of Pathology & Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, CanadaBritish Columbia Cancer Agency, Vancouver Centre, Vancouver, British Columbia, Canada; Corresponding author. Address for correspondence: Sophie Sun, MD, MSc, FRCPC, Division of Medical Oncology, Faculty of Medicine, British Columbia Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia, Canada V5Z 4E6.Introduction: EML4-ALK rearrangements represent an oncogenic driver alteration in 5% of NSCLC cases. We aim to better understand real-world treatment patterns and outcomes of ALK fusion-positive (ALK+) patients with advanced-stage NSCLC. Methods: We performed a retrospective population-based chart review of ALK+ patients with locally advanced or metastatic NSCLC in British Columbia (BC), Canada. Patients diagnosed from January 2014 to May 2023 were identified through the BC Cancer Genetics Laboratory database, and data were collected up to December 2023. Results: A total of 216 patients with stage IIIB, IIIC, or IV ALK+ lung NSCLC were identified. Median age was 60 (range: 24–91) years, 151 (68.9%) had never smoked, and 95 (43.9%) were Asian. The median overall survival was 49.4 months with median follow-up time of 55.4 months. Majority of the cohort (n = 198, 91.7%) received palliative systemic therapy, all of which included at least one ALK tyrosine kinase inhibitor (TKI). The most common first-line regimen was alectinib (n = 97, 49.0%) followed by crizotinib (n = 84, 42.4%); only four and one patient received lorlatinib and brigatinib first line, respectively. Alectinib was frequently prescribed overall, with 80.3% of patients receiving it in any treatment line. Time to treatment discontinuation was significantly longer (p < 0.0001) on first-line alectinib at 22.9 months as compared with 10.9 months for crizotinib. Conclusions: Patients with ALK+ advanced NSCLC in BC have durable responses to ALK TKIs. Despite approval of all ALK TKIs for first-line use since 2021, alectinib is largely the favored agent in BC. Further real-world investigations can refine treatment strategies and shape policies around ALK TKIs for patients with ALK+ NSCLC.http://www.sciencedirect.com/science/article/pii/S2666364324000675NSCLCTargeted therapyALKReal-worldTreatment sequencing |
| spellingShingle | Peiyao Wang, BSc Curtis Hughesman, PhD Stephen Yip, MD, PhD, FRCPC William W. Lockwood, PhD Sophie Sun, MD, MSc, FRCPC Brief Report: Real-World Treatment Patterns and Clinical Outcomes for Patients With Advanced ALK-Rearranged NSCLC in British Columbia JTO Clinical and Research Reports NSCLC Targeted therapy ALK Real-world Treatment sequencing |
| title | Brief Report: Real-World Treatment Patterns and Clinical Outcomes for Patients With Advanced ALK-Rearranged NSCLC in British Columbia |
| title_full | Brief Report: Real-World Treatment Patterns and Clinical Outcomes for Patients With Advanced ALK-Rearranged NSCLC in British Columbia |
| title_fullStr | Brief Report: Real-World Treatment Patterns and Clinical Outcomes for Patients With Advanced ALK-Rearranged NSCLC in British Columbia |
| title_full_unstemmed | Brief Report: Real-World Treatment Patterns and Clinical Outcomes for Patients With Advanced ALK-Rearranged NSCLC in British Columbia |
| title_short | Brief Report: Real-World Treatment Patterns and Clinical Outcomes for Patients With Advanced ALK-Rearranged NSCLC in British Columbia |
| title_sort | brief report real world treatment patterns and clinical outcomes for patients with advanced alk rearranged nsclc in british columbia |
| topic | NSCLC Targeted therapy ALK Real-world Treatment sequencing |
| url | http://www.sciencedirect.com/science/article/pii/S2666364324000675 |
| work_keys_str_mv | AT peiyaowangbsc briefreportrealworldtreatmentpatternsandclinicaloutcomesforpatientswithadvancedalkrearrangednsclcinbritishcolumbia AT curtishughesmanphd briefreportrealworldtreatmentpatternsandclinicaloutcomesforpatientswithadvancedalkrearrangednsclcinbritishcolumbia AT stephenyipmdphdfrcpc briefreportrealworldtreatmentpatternsandclinicaloutcomesforpatientswithadvancedalkrearrangednsclcinbritishcolumbia AT williamwlockwoodphd briefreportrealworldtreatmentpatternsandclinicaloutcomesforpatientswithadvancedalkrearrangednsclcinbritishcolumbia AT sophiesunmdmscfrcpc briefreportrealworldtreatmentpatternsandclinicaloutcomesforpatientswithadvancedalkrearrangednsclcinbritishcolumbia |